StudyFinder

Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)

Status: Recruiting

To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for missing doses of medication. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.

I'm interested

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• fluent in written and spoken English or Spanish
• diagnosis of new or established hormone receptor (HR)+ HER2- metastatic breast cancer
• started taking any of the CKD4/6 inhibitor drugs (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) in the last 30 days before consenting or have received a prescription and plan to start taking within the 30 days after consent
• must have an email address
• at least able to do limited selfcare; confined to bed or chair more than 50% of waking hours
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors
• previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio
Interventions:

Other: Electronic Health Record Review, Other: Health Promotion and Education, Procedure: Health Telemonitoring, Other: Interview, Behavioral: Patient Navigation, Other: Survey Administration, Other: Text Message-Based Navigation Intervention

Conditions:

Cancer

Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Puneet Cheema
Phase: NA
IRB Number: MMCORC098
See this study on ClinicalTrials.gov

Back